+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "FDA Form 483"

Establishing a Robust Data Integrity Program - Webinar (Recorded) - Product Thumbnail Image

Establishing a Robust Data Integrity Program - Webinar (Recorded)

  • Webinar
  • February 2019
  • 90 Minutes
  • Global
The Most Serious FDA 483s - How to Avoid Them - Product Thumbnail Image

The Most Serious FDA 483s - How to Avoid Them

  • Training
  • 90 Minutes
  • Global
Major CGMP Issues - US FDA Concerns in 2022 - Product Thumbnail Image

Major CGMP Issues - US FDA Concerns in 2022

  • Training
  • 90 Minutes
  • United States
Equipment Qualification Basics - Product Thumbnail Image

Equipment Qualification Basics

  • Training
  • 90 Minutes
  • Global
Computer System Validation and Part 11 Compliance - Product Thumbnail Image

Computer System Validation and Part 11 Compliance

  • Training
  • 60 Minutes
  • Global
Loading Indicator

The FDA Form 483 market is a subset of the pharmaceutical manufacturing industry. It is a regulatory document issued by the U.S. Food and Drug Administration (FDA) to a pharmaceutical manufacturing facility after an inspection. The form is used to document any observed violations of the FDA's Current Good Manufacturing Practice (CGMP) regulations. It is a critical tool for the FDA to ensure that pharmaceutical products are safe and effective. The FDA Form 483 market is composed of pharmaceutical manufacturers, contract manufacturers, and other related companies. Companies in this market include Pfizer, Merck, Novartis, GlaxoSmithKline, Sanofi, Johnson & Johnson, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more